Endometriotic BX795 solubility ovarian cyst and endometriosis- associated ovarian cancer. Int J Gynecol
Endometriotic ovarian cyst and endometriosis- associated ovarian cancer. Int J Gynecol Cancer 2014, 24(1):36?2. 8. Jian-Feng W, Dong-Qiu D: Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol 2007, 13:5692?698. 9. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59:2307?312. 10. Yamagata Y, Nishino K, Takaki E, Sato S, Maekawa R, Nakai A, Sugino N: Genome-wide DNA methylation profiling in cultured eutopic and ectopic endometrial stromal cells. PLoS One 2014, 9(1):e83612.11. Ren F, Wang DB, Li T: Epigenetic inactivation of SPOCK2 in the malignant transformation of ovarian endometriosis. Zhonghua Fu Chan Ke Za Zhi 2011, 46(11):822?25. 12. Shi H, Li Y, Wang X, Lu C, Yang L, Gu C, Xiong J, Huang Y, Wang S, Lu M: Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. PLoS One 2013, 8:e76787. 13. Vigan?P, Somigliana E, Parazzini F, Vercellini P: Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 2007, 88:588?93. 14. Arasaradnam RP, Khoo K, Bradburn M, Mathers JC, Kelly SB: DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28506461 with ulcerative colitis (UC). Epigenetics 2010, 5(5):422?26. 15. Meyer JL, Zimbardi D, Podgaec S, Amorim RL, Abr MS, Rainho CA: DNA methylation patterns of steroid receptor genes ESR1, ESR2 and PGR in deep endometriosis compromising the rectum. Int J Mol Med 2014, 33(4):897?04. 16. Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, Tokunaga H, Utsunomiya H, Yin P, Luo X, Lin Z, Imir G, Thung S, Su EJ, Kim JJ: Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med 2010, 28(1):36?3. 17. Xiao W, Awadallah A, Xin W: Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012, 5(7):642?50. 18. Lin K, Zhan H, Ma J, Xu K, Wu R, Zhou C, Lin J: Increased steroid receptor RNA activator protein (SRAP) accompanied by decreased estrogen receptor-beta (ER-) levels during the malignant transformation of endometriosis associated ovarian clear cell carcinoma. Acta Histochem 2014, S0065?281(14):00044. 19. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D, Salto-Tellez M, Ito K, Ito Y, Chen LF: RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor . Oncogene 2012, 31(4):527?34. 20. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ: RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003, 278:28045?8051. 21. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH: Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010, 9:264. 22. Maruyama R, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27385778 Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, Yamamoto E, Nojima M, Fujikane T, Sasaki Y, Yamashita T, Watanabe Y, Hiratsuka H, Hirata K, Itoh F, Imai K, Shinomura Y, Tokino T: Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 2008, 29:1312?318. 23. Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M, Tachikawa T: K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc.
